NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...